0001209191-17-049702.txt : 20170821
0001209191-17-049702.hdr.sgml : 20170821
20170821161509
ACCESSION NUMBER: 0001209191-17-049702
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170817
FILED AS OF DATE: 20170821
DATE AS OF CHANGE: 20170821
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dumas Jacques
CENTRAL INDEX KEY: 0001598640
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35837
FILM NUMBER: 171043262
MAIL ADDRESS:
STREET 1: C/O IDENIX PHARMACEUTICALS, INC.
STREET 2: 320 BENT STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TETRAPHASE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001373707
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 ARSENAL STREET
STREET 2: SUITE 110
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617.715.3600
MAIL ADDRESS:
STREET 1: 480 ARSENAL STREET
STREET 2: SUITE 110
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-08-17
0
0001373707
TETRAPHASE PHARMACEUTICALS INC
TTPH
0001598640
Dumas Jacques
C/O TETRAPHASE PHARMACEUTICALS, INC.
480 ARSENAL STREET
WATERTOWN
MA
02472
0
1
0
0
Chief ScientificOfficer
Common Stock
2017-08-17
4
S
0
7155
5.86
D
0
D
On January 6, 2016, the Reporting person was granted 35,000 restricted stock units ("RSUs")( the "2016 RSU grant") that were previously reported on Table II Of Form 4, which form was filed with the Securities and Exchange Commission on June 10, 2016. Of the 2016 RSU grant, 11,667 shares vested on January 6, 2017 of which 4,512 shares were withheld by the Issuer to satisfy the reporting person's tax withholding obligations in connection with the delivery of the conversion of the RSUs into common stock on the vesting date. The remaining 7,155 shares were sold on August 17, 2017 and such sale is reported on this Form 4.
The sale of these shares of common stock reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 16, 2017.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $5.79 to $5.90 per share. The reporting person undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
/s/Maria Stahl as Attorney-in-Fact for Jacques Dumas
2017-08-21